Search clinical trials for: Ruxolitinib Phosphate Cream

Total 5262 results

Incyte Corporation

Approved for marketing

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Graft-versus-host Disease (GVHD)
Incyte Corporation

No longer available

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

COVID-19
University Health Network, Toronto

Terminated

Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia

COVID-19 | Pneumonia

Canada
Pfizer

Completed

A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test

Psoriasis

Germany
University of North Carolina, Charlotte
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis (MSSkin)

Multiple Sclerosis

United States
Marcelo Iastrebner
Novartis

Unknown

Ruxolitinib in the Treatment of Covid-19

COVID-19
Azienda USL Toscana Nord Ovest
Azienda Ospedaliero, Universitaria Pisana; Azienda Ospedaliera Universitaria... and other collaborators

Unknown

Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection (RESPIRE)

Severe Acute Respiratory Syndrome Coronavirus 2
Dana-Farber Cancer Institute

Terminated

Ruxolitinib in Patients With Breast Cancer

Breast Cancer

United States
Chinese PLA General Hospital

Completed

Low Dose Ruxolitinib in Combination With Methylprednisolone

Stem Cell Transplant Complications | aGVHD

China
Edesa Biotech Inc.
JSS Medical Research Inc.

Active, not recruiting

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

Allergic Contact Dermatitis

United States, Canada
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Centre Hospitalier Universitaire de Nice

Recruiting

Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas (PREVENT)

Vitiligo

France
Novartis Pharmaceuticals
Incyte Corporation

Completed

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)

Cytokine Storm (Covid-19)

United States, Colombia, Turkey, Spain, United Kingdom, Germany, Peru, Russian Federation, Brazil, France, Mexico, Argentina
Grupo Cooperativo de Hemopatías Malignas

Completed

Treatment of SARS Caused by COVID-19 With Ruxolitinib

COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2

Mexico
Kartos Therapeutics, Inc.

Unknown

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Polycythemia Vera

United States, Poland, Spain, Germany, Hungary, France
LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
John Mascarenhas
National Cancer Institute (NCI); Novartis; Incyte Corporation; Myeloproliferative...

Terminated

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Primary Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Canada, United Kingdom
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
GlaxoSmithKline

Completed

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

Dermatitis, Atopic

United States, Canada, Japan
Geron Corporation

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Myelofibrosis

United States
GlaxoSmithKline

Completed

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

Psoriasis

United States, Canada, Japan
Innovaderm Research Inc.

Recruiting

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus

Discoid Lupus Erythematosus

Canada
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

Chronic Hand Eczema

Belgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Chronic Hand Eczema

Canada, France, Germany, Italy, Poland, United Kingdom
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia
Medical University of Silesia

Completed

Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With TMD

Cannabis | Myofascial Pain | Temporomandibular Disorder | Electromyography

Poland
AmDerma

Completed

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

Actinic Keratosis

United States
One World Cannabis Ltd.

Completed

A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

Safety Study for Future Treatment of Psoriasis

Israel
AmDerma
International Dermatology Research, Inc.

Completed

Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis

Plaque Psoriasis

Dominican Republic
Medical University of Lodz

Completed

The Efficacy of a Cosmetic Preparation Containing Sheep Colostrum on Mature Skin (COLMATSKIN)

Skin Aging

Poland
AstraZeneca
Fougera Pharmaceuticals Inc.

Withdrawn

A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis
Serentis Ltd.

Completed

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Pruritus, Atopic Dermatitis

United States
Angelos Kassianos
German Oncology Center, Cyprus; RSL Revolutionary Labs Ltd

Not yet recruiting

Prevention of Radiodermatitis in Breast and Head and Neck Cancer Patients in Cyprus (MEDISKIN)

Breast Cancer | Head and Neck Cancer

Cyprus
Sixera Pharma

Recruiting

A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

Netherton Syndrome

France
AstraZeneca
Fougera Pharmaceuticals Inc.

Withdrawn

A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

Dermatitis
LEO Pharma

Completed

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia

United States
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Atopic Dermatitis Eczema

United States, Canada
Peking Union Medical College Hospital

Recruiting

The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia

Severe Checkpoint Inhibitor Pneumonitis

China
M.D. Anderson Cancer Center
Incyte Corporation

Terminated

Phase l/II Study of Ruxolitinib for Acute Leukemia

Leukemia

United States
Washington University School of Medicine
Rigel Pharmaceuticals

Terminated

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Myelofibrosis | Thrombocytopenia

United States
Ascentage Pharma Group Inc.

Withdrawn

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Myelofibrosis

United States
Prisma Health-Upstate

Completed

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

COVID19 | Cytokine Release Syndrome

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

Myelofibrosis

Italy, United States, Canada, Germany
Sunnybrook Health Sciences Centre
Novartis

Unknown

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Leukemia, Lymphocytic, Chronic, B-Cell

Canada
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Oncology Institute of Southern Switzerland

Withdrawn

Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Prostate Cancer

Switzerland
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Blasts More Than 20 Percent of Bone Marrow Nucleated Cells | Blasts More Than 20 Percent of Peripheral Blood White Cells

United States

3

Subscribe